反应详情

The title compound was prepared in two steps in a manner similar to that described in Example 191 from methyl [7-bromo-4-(3,4-dimethylphenyl)-2-methyl-1-oxo-1,2-dihydro-3-isoquinolinyl][(1,1-dimethylethyl)oxy]acetate and 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and was isolated as a pale yellow solid (20 mg, 57%) after reverse phase chromatography as the trifluoroacetate salt: 1H NMR (400 MHz, CHLOROFORM-d) δ=8.59 (s, 1 H), 7.91 (s, 1 H), 7.82 (s, 1 H), 7.70-7.53 (m, 1 H), 7.45-7.31 (m, 1 H), 7.32-7.22 (m, 1 H), 7.17 (dd, J=8.5, 12.4 Hz, 1 H), 7.12-7.03 (m, 1 H), 5.36 (d, J=1.0 Hz, 1 H), 4.00 (s, 3 H), 3.73 (s, 3 H), 2.38 (s, 3 H), 2.33 (d, J=2.5 Hz, 3 H), 1.07 (d, 9 H); LC/MS (m/z) ES+=474 (M+1).